Generic Name and Formulations:
Erenumab-aooe 70mg/mL; soln for SC inj; preservative-free.
Indications for AIMOVIG:
Prophylaxis of migraine.
Give by SC inj into abdomen, thigh, or upper arm. 70mg once monthly; some patients may benefit from 140mg (given as 2 consecutive 70mg inj) once monthly.
Do not inj into tender, bruised, red, or hard areas. Latex allergy. Elderly. Pregnancy. Nursing mothers.
Calcitonin gene-related peptide (CGRP) receptor antagonist.
Inj site reactions, constipation, cramps, muscle spasms.
Single-dose prefilled SureClick autoinjectors—1, 2; Single-dose prefilled syringes—1, 2
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics